FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1630159102> ?p ?o ?g. }

• W1630159102 endingPage "193" @default.
• W1630159102 startingPage "177" @default.
• W1630159102 abstract "IL-13 is a pleiotropic Th2 cytokine considered likely to play a pivotal role in asthma. Here we describe the preclinical in vitro and in vivo characterization of CAT-354, an IL-13-neutralizing IgG4 monoclonal antibody (mAb), currently in clinical development.In vitro the potency, specificity and species selectivity of CAT-354 was assayed in TF-1 cells, human umbilical vein endothelial cells and HDLM-2 cells. The ability of CAT-354 to modulate disease-relevant mechanisms was tested in human cells measuring bronchial smooth muscle calcium flux induced by histamine, eotaxin generation by normal lung fibroblasts, CD23 upregulation in peripheral blood mononuclear cells and IgE production by B cells. In vivo CAT-354 was tested on human IL-13-induced air pouch inflammation in mice, ovalbumin-sensitization and challenge in IL-13 humanized mice and antigen challenge in cynomolgus monkeys.CAT-354 has a 165 pM affinity for human IL-13 and functionally neutralized human, human variant associated with asthma and atopy (R130Q) and cynomolgus monkey, but not mouse, IL-13. CAT-354 did not neutralize human IL-4. In vitro CAT-354 functionally inhibited IL-13-induced eotaxin production, an analogue of smooth muscle airways hyperresponsiveness, CD23 upregulation and IgE production. In vivo in humanized mouse and cynomolgus monkey antigen challenge models CAT-354 inhibited airways hyperresponsiveness and bronchoalveolar lavage eosinophilia.CAT-354 is a potent and selective IL-13-neutralizing IgG4 mAb. The preclinical data presented here support the trialling of this mAb in patients with moderate to severe uncontrolled asthma." @default.
• W1630159102 created "2016-06-24" @default.
• W1630159102 creator A5000898962 @default.
• W1630159102 creator A5012902501 @default.
• W1630159102 creator A5014848651 @default.
• W1630159102 creator A5021174237 @default.
• W1630159102 creator A5028626019 @default.
• W1630159102 creator A5029309856 @default.
• W1630159102 creator A5041013176 @default.
• W1630159102 creator A5052146359 @default.
• W1630159102 creator A5053582746 @default.
• W1630159102 creator A5054194265 @default.
• W1630159102 creator A5055447846 @default.
• W1630159102 creator A5056503561 @default.
• W1630159102 creator A5059759145 @default.
• W1630159102 creator A5074632444 @default.
• W1630159102 creator A5076292362 @default.
• W1630159102 creator A5077729208 @default.
• W1630159102 creator A5085094521 @default.
• W1630159102 date "2012-04-10" @default.
• W1630159102 modified "2023-10-06" @default.
• W1630159102 title "Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma" @default.
• W1630159102 cites W1557765112 @default.
• W1630159102 cites W1630729294 @default.
• W1630159102 cites W1835748585 @default.
• W1630159102 cites W1929857088 @default.
• W1630159102 cites W1930202916 @default.
• W1630159102 cites W1969912242 @default.
• W1630159102 cites W1971886437 @default.
• W1630159102 cites W1974518055 @default.
• W1630159102 cites W1975847098 @default.
• W1630159102 cites W1979129445 @default.
• W1630159102 cites W1979492370 @default.
• W1630159102 cites W1989048950 @default.
• W1630159102 cites W1989055057 @default.
• W1630159102 cites W1990562459 @default.
• W1630159102 cites W2002135161 @default.
• W1630159102 cites W2011677425 @default.
• W1630159102 cites W2030657137 @default.
• W1630159102 cites W2032711986 @default.
• W1630159102 cites W2042905970 @default.
• W1630159102 cites W2060763719 @default.
• W1630159102 cites W2064243251 @default.
• W1630159102 cites W2070529127 @default.
• W1630159102 cites W2077412476 @default.
• W1630159102 cites W2078536531 @default.
• W1630159102 cites W2085580349 @default.
• W1630159102 cites W2087940407 @default.
• W1630159102 cites W2093023410 @default.
• W1630159102 cites W2097346494 @default.
• W1630159102 cites W2104852612 @default.
• W1630159102 cites W2107207387 @default.
• W1630159102 cites W2108836360 @default.
• W1630159102 cites W2112578120 @default.
• W1630159102 cites W2112970562 @default.
• W1630159102 cites W2114406337 @default.
• W1630159102 cites W2115179641 @default.
• W1630159102 cites W2118102780 @default.
• W1630159102 cites W2118643159 @default.
• W1630159102 cites W2123733931 @default.
• W1630159102 cites W2124566107 @default.
• W1630159102 cites W2125805192 @default.
• W1630159102 cites W2129249696 @default.
• W1630159102 cites W2132665714 @default.
• W1630159102 cites W2135298542 @default.
• W1630159102 cites W2140033514 @default.
• W1630159102 cites W2149810044 @default.
• W1630159102 cites W2150773437 @default.
• W1630159102 cites W2151599364 @default.
• W1630159102 cites W2154156503 @default.
• W1630159102 cites W2157566717 @default.
• W1630159102 cites W2163544819 @default.
• W1630159102 cites W2168421693 @default.
• W1630159102 cites W2185707773 @default.
• W1630159102 cites W4237593666 @default.
• W1630159102 doi "https://doi.org/10.1111/j.1476-5381.2011.01659.x" @default.
• W1630159102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3415647" @default.
• W1630159102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21895629" @default.
• W1630159102 hasPublicationYear "2012" @default.
• W1630159102 type Work @default.
• W1630159102 sameAs 1630159102 @default.
• W1630159102 citedByCount "90" @default.
• W1630159102 countsByYear W16301591022012 @default.
• W1630159102 countsByYear W16301591022013 @default.
• W1630159102 countsByYear W16301591022014 @default.
• W1630159102 countsByYear W16301591022015 @default.
• W1630159102 countsByYear W16301591022016 @default.
• W1630159102 countsByYear W16301591022017 @default.
• W1630159102 countsByYear W16301591022018 @default.
• W1630159102 countsByYear W16301591022019 @default.
• W1630159102 countsByYear W16301591022020 @default.
• W1630159102 countsByYear W16301591022021 @default.
• W1630159102 countsByYear W16301591022022 @default.
• W1630159102 countsByYear W16301591022023 @default.
• W1630159102 crossrefType "journal-article" @default.
• W1630159102 hasAuthorship W1630159102A5000898962 @default.
• W1630159102 hasAuthorship W1630159102A5012902501 @default.
• W1630159102 hasAuthorship W1630159102A5014848651 @default.

• next